Trials / Completed
CompletedNCT04324489
DAS181 for Severe COVID-19: Compassionate Use
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Renmin Hospital of Wuhan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to investigate the safety and potential efficacy of DAS181 for the treatment of severe COVID-19.
Detailed description
Each eligible subject is treated with DAS181 for 10 days and observed for 28 days from the first day of administration. From day 1 to 10, once or twice a day, for 10 consecutive days, a total of 9 mg (7 ml) nebulized DAS181 is given. If DAS181 is given by twice a day, one vial containing 4.5 mg (3.5m1) DAS181 should be delivered with about 12-hour interval.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DAS181 | Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days. |
Timeline
- Start date
- 2020-03-06
- Primary completion
- 2020-04-16
- Completion
- 2020-04-30
- First posted
- 2020-03-27
- Last updated
- 2020-05-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04324489. Inclusion in this directory is not an endorsement.